Sweat, Tears... but no Blood

• GraphWear Technologies is developing a skin-surface-level wearable made of graphene that will unlock needle-free glucose monitoring for the 35M+ Americans & 450M+ people globally who live with diabetes
• GraphWear was founded in 2015 by Rajatesh Gudibande and Saurabh Radhakrishnan, both of whom have Masters' degrees in nanotechnology from the University of Pennsylvania
• Eventually GraphWear plans to extend their technology platform for other chronic illnesses, like heart disease. Their team has already patented a way to use polarized fluids as transistors that could be useful beyond sensing glucose.
• $20.5M Series B round was led by Mayfield Fund, with participation from MissionBio Capital, Builders VC and VSC Ventures. This current round should take Graphwear into final phase of FDA approvals.
• While Series B rounds aren't core to VSC Ventures' focus, we got comfortable with this deal given the strength of the management team, experienced syndicate of co-investors, strong alignment with VSCs Wellness practice, and reasonable valuation given the product maturity.

TechCrunch article linked here(check out another VSC Ventures shoutout—That's 2 mentions in 2 months!)

For VSC Ventures LPs: We have a detailed written deal memo available upon request